Savara SVRA EBITDA

EBITDA at other companies

Innoviva, Inc.INVA

$57.46M+4.0%

XER

Xeris Biopharma Holdings, Inc.XERS

$5.5M+14.3%

Zevra Therapeutics, Inc.ZVRA

$17.14M+125%

Upstream Bio, Inc.UPB

-$43.57M-36.3%

ANI PharmaceuticalsANIP

$60.1M+61.7%

PVL

Palvella TherapeuticsPVLA

-$1.79M—

FAQ

What is Savara's EBITDA?

Savara (SVRA) reported EBITDA of -$38.97M in Q1 2026.

How has Savara's EBITDA changed year-over-year?

Savara's EBITDA decreased by 37.2% year-over-year, from -$28.41M to -$38.97M.

What is the long-term trend for Savara's EBITDA?

Over 3 years (2021 to 2024), Savara's EBITDA has grown at a 35.6% compound annual growth rate (CAGR), from -$41.34M to -$103.07M.

What does EBITDA mean?

Earnings before interest, taxes, depreciation, and amortization — EBIT plus the D&A add-back from the cash-flow statement (EBITDA = EBIT + D&A). A proxy for cash earnings that strips out financing, tax, and non-cash charges.